Sarepta Therapeutics | SRPT - 税前利润



金融业
股票价格
USD
资产
USD 3.35B
现金及等价物
USD 801.28M
销售成本
USD 399.39M
流动资产
USD 2.54B
流动负债
USD 1.1B
债务
USD 1.25B
EBIT
USD -410.08M
EBITDA
USD -168.03M
员工
1.37K
EPS每股收益
USD -3.58
股本和储备
USD 1.14B
销售毛利
USD 43.55M
债务利息支出
USD 7.56M
利息收入
USD 8.38M
贷款资金
USD 828.97M
市值
USD 1.98B
净收入
USD -412.23M
营业费用
USD 853.02M
营业利润
USD -410.08M
普通股股本
USD 104.96M
PE价格收益
27.27
税前利润
USD -407.68M
销售收入
USD 442.9M
销售和管理费用
USD 105.38M
股票
USD 914.74M
贸易债权人
USD 280.84M
应收帐款人
USD 398.23M


税前利润 更改 日
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD -56M 613.3M 2025-12
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Capricor Therapeutics USD -30.17M 5.6M 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
Incyte USD 389.94M 92.37M 2025-12
Insmed USD -326.93M 41.77M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Moderna USD -187M 631M 2025-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Tectonic Therapeutic USD -18.97M 63K 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09